ASCO 2026 preview – Pumitamig looks similar to ivonescimab again
First global data, from Rosetta Lung-02 in first-line NSCLC, tell a familiar story.
Pfizer targets VEGF bispecific white space
The company diverges from Summit and Bristol/BioNTech with a pivotal endometrial trial.
Crossover hits Compass
The Companion-002 trial of tovecimig fails to show an overall survival benefit versus chemo.
AbbVie and RemeGen’s bispecific goes pivotal
Chinese trials in first-line NSCLC and colorectal cancer are imminent.
Compass points the way towards its next readout
Progression-free and overall survival data from Companion-002 are due this quarter.
The relentless march of VEGF bispecifics
Two new pivotal Chinese first-line trials have started in lung cancer.
Pfizer mimics pumitamig in gastroesophageal cancers
The company will start a phase 2/3 trial of PF-08634404 in March.
Pumitamig pivotal trials come in pairs
Bristol will test the bispecific in two new lung indications.
Huabo goes pivotal with bispecific VEGF trap
The company takes a PD-L1 x VEGF asset into phase 3.
